Brown on Data From the Phase 3 ALPINE Trial of Zanubrutinib in R/R CLL
June 28th 2023Jennifer R. Brown, MD, PhD, highlights the results from the phase 3 ALPINE study evaluating the treatment with zanubrutinib for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Watch
TALAPRO-2 Data Support Approval of Talazoparib/Enzalutamide in HRR-Mutant mCRPC
June 21st 2023Karim Fizazi, MD, discusses findings from the phase 3 TALAPRO-2 trial which support the recent FDA approval of talazoparib plus enzalutamide in homologous recombination repair gene-mutated metastatic castration resistant prostate cancer.
Watch